Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia
Study ID: NCT04303377
Phase: PHASE2
Status: Withdrawn

Conditions

ST-elevation Myocardial Infarction

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Evolocumab — BIOLOGICAL
Evolocumab 140 mg every 2 weeks plus Standard of Care, including optimal lipid lowering treatment (high dose of statin ± ezetimibe)

Study Details

This is a prospective, multi-centre, open label, randomised study of Phase II that enrolls patients hospitalized with a diagnosis of ST-elevation myocardial infarction (STEMI), comparing Evolocumab versus Standard of Care.

Key Dates

Start date: Nov 18, 2019
Status verified: Nov 2024
Primary completion: Jan 2, 2020
Completion: Jul 24, 2020

Study Design

Enrollment: 0 participants (actual)
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Arms

Experimental: Evolocumab
Evolocumab administration in the acute phase of ST elevation myocardial infarction
No Intervention: Standard of care

Primary Outcome Measure

Infarct Size reduces infarct size in patients with STEMI undergoing primary PCI [ Time Frame: 6 months Visit ]